Modulation of 5-fluorouracil cytotoxicity through thymidylate synthase and NF-κB down-regulation and its application on the radiolabelled iododeoxyuridine therapy on human hepatoma cell

Biochemical Pharmacology

Volumn 69, Issue 4, 2005, Pages 617-626

  Wang, Hsin Ell ^a   Wu, Hui Chuan ^b   Kao, Shang Jyh ^b   Tseng, Fan Wei ^b   Wang, Yu Shan ^b   Yu, Hung Man ^a   Chou, Shun Lan ^a   Yen, Sang Hue ^a   Chi, Kwan Hwa ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

5 FU; Iododeoxyuridine; NF B; PB; PDTC; Thymidylate synthase

Indexed keywords

ANTIOXIDANT; ARYLBUTYRIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; FATTY ACID DERIVATIVE; FLUOROURACIL; IDOXURIDINE I 125; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRROLIDINODITHIOCARBAMATE; RADIOPHARMACEUTICAL AGENT; THIOL DERIVATIVE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; FLUOROURACIL; HUMANS; IDOXURIDINE; IODINE RADIOISOTOPES; LIVER NEOPLASMS; NF-KAPPA B; PHENYLBUTYRATES; PROLINE; THIOCARBAMATES; THYMIDYLATE SYNTHASE;

EID: 12744265257     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.11.006     Document Type: Article

References (49)

1. T.J. Kinsella, J.B. Mitchell, A. Russo, G. Morstyn, and E. Glatstein The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers Int J Radiat Oncol Biol Phys 10 1984 1399 1406
2. K.D. Bagshawe, K. Sharma, P.J. Southall, J.A. Boden, G.M. Boxer, and T.A. Patridge Selective uptake of toxic nucleoside (125IUdR) by resistant cancer Br J Radiol 64 1991 37 44
3. K.H. Chi, H.E. Wang, F.D. Chen, Y. Chao, R.S. Liu, and S.L. Chou Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model J Nucl Med 42 2001 345 351
4. 131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire Br J Cancer 77 1998 385 390
5. A.I. Kassis, and S.J. Adelstein 5-[125]iodo-2′-deoxyuridine in the radiotherapy of solid CNS tumors in rats Acta Oncol 35 1996 935 939
6. J. Pressacco, D.W. Hedley, and C. Erlichman ICI D1694 and idoxuridine: a synergistic antitumor combination Cancer Res 54 1994 3772 3778
7. 125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors Eur J Cancer 32A 1996 1603 1608
8. Y. Huang, and S. Waxman Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate Clin Cancer Res 4 1998 2503 2509
9. Y. Huang, C.M. Horvath, and S. Waxman Re-growth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate Cancer Res 60 2000 3200 3206
10. R. Chinery, J.A. Brockman, M.O. Peeler, Y. Shyr, R.D. Beauchamp, and R.J. Coffey Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta Nat Med 3 1997 1233 1241
11. S.P. Bach, R. Chinery, S.T. O'Dwyer, C.S. Potten, R.J. Coffey, and A.J. Watson Pyrrolidinedithiocarbamate increases the therapeutic index of 5-fluorouracil in a mouse model Gastroenterology 118 2000 81 89
12. Y. Saga, M. Suzuki, H. Mizukami, T. Kohno, Y. Takei, and M. Fukushima Overexpression of thymidylate synthase mediates desensitization for 5-fluorouracil of tumor cells Int J Cancer 106 2003 324 326
13. E.R. Camp, J. Li, D.J. Minnich, A. Brank, L.L. Moldawer, and S.L. MacKay Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer J Am Coll Surg 199 2004 249 258
14. C.F. Foulon, S.J. Adelstein, and A.I. Kassis Kit formulation for the preparation of radiolabeled iododeoxyuridine by demetallation J Nucl Med 37 1996 1S 3S
15. M. Derenzini, L. Montanaro, D. Trere, A. Chilla, P.L. Tazzari, and F. Dall'Olio Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines Mol Pathol 55 2002 310 314
16. J.H. Wang, B.J. Manning, Q.D. Wu, S. Blankson, D. Bouchier-Hayes, and H.P. Redmond Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism J Immunol 170 2003 795 804
17. W.H. Xiao, Y.M. Dupertuis, B. Mermillod, L.Q. Sun, N. de Tribolet, and F. Buchegger Unlabelled iododeoxyuridine increases the cytotoxicity and incorporation of [1251]-iododeoxyuridine in two human glioblastoma cell lines Nucl Med Commun 21 2000 947 953
18. K.D. Bagshawe Reversed-role chemotherapy for resistant cancer Lancet 2 1986 778 781
19. S.I. Matsui, M.A. Arredondo, C. Wrzosek, and Y.M. Rustum DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells Cancer Res 56 1996 4715 4723
20. C.I. Nobel, M. Kimland, B. Lind, S. Orrenius, and A.F. Slater Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper J Biol Chem 270 1995 26202 26208
21. P. Brennan, and L.A. O'Neill 2-mercaptoethanol restores the ability of nuclear factor kappa B (NF kappa B) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC). Evidence for oxidation of glutathione in the mechanism of inhibition of NF kappa B by PDTC Biochem J 320 Pt 3 1996 975 981
22. R. Chinery, R.D. Beauchamp, Y. Shyr, S.C. Kirkland, R.J. Coffey, and J.D. Morrow Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells Cancer Res 58 1998 2323 2327
23. S. Nakao, Y. Ogtata, E. Shimizu, M. Yamazaki, S. Furuyama, and H. Sugiya Tumor necrosis factor alpha (TNF-alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts Mol Cell Biochem 238 2002 11 18
24. J.A. DiGiuseppe, L.J. Weng, K.H. Yu, S. Fu, M.B. Kastan, and D. Samid Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis Leukemia 13 1999 1243 1253
25. P.G. Johnston, H.J. Lenz, C.G. Leichman, K.D. Danenberg, C.J. Allegra, and P.V. Danenberg Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res 55 1995 1407 1412
26. C.G. Leichman, H.J. Lenz, L. Leichman, K. Danenberg, J. Baranda, and S. Groshen Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J Clin Oncol 15 1997 3223 3229
27. M.C. Etienne, M. Chazal, P. Laurent-Puig, N. Magne, C. Rosty, and J.L. Formento Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses J Clin Oncol 20 2002 2832 2843
28. A. Tomiak, M. Vincent, C.C. Earle, P.G. Johnston, W. Kocha, and M. Taylor Thymidylate synthase expression in stage II and III colon cancer: a retrospective review Am J Clin Oncol 24 2001 597 602
29. C. Aschele, D. Debernardis, G. Tunesi, F. Maley, and A. Sobrero Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil Clin Cancer Res 6 2000 4797 4802
30. W.L. Washtien Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil Mol Pharmacol 25 1984 171 177
31. D.B. Longley, P.R. Ferguson, J. Boyer, T. Latif, M. Lynch, and P. Maxwell Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies Clin Cancer Res 7 2001 3533 3539
32. M. Fukushima, A. Fujioka, J. Uchida, F. Nakagawa, and T. Takechi Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo Eur J Cancer 37 2001 1681 1687
33. D.B. Longley, J. Boyer, W.L. Allen, T. Latif, P.R. Ferguson, and P.J. Maxwell The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates Cancer Res 62 2002 2644 2649
34. E. Chu, D.M. Koeller, P.G. Johnston, S. Zinn, and C.J. Allegra Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma Mol Pharmacol 43 1993 527 533
35. R.A. Bras-Goncalves, M. Pocard, J.L. Formento, F. Poirson-Bichat, G. De Pinieux, and I. Pandrea Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis Gastroenterology 120 2001 874 888
36. M. Barkett, and T.D. Gilmore Control of apoptosis by Rel/NF-kappaB transcription factors Oncogene 18 1999 6910 6924
37. Y. Yamamoto, and R.B. Gaynor Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer J Clin Invest 107 2001 135 142
38. M. Meli, N. D'Alessandro, M. Tolomeo, L. Rausa, M. Notarbartolo, and L. Dusonchet NF-kappaB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines Ann N Y Acad Sci 1010 2003 232 236
39. W. Wang, and J. Cassidy Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells Br J Cancer 88 2003 624 629
40. X. Bian, A.W. Opipari Jr., A.B. Ratanaproeksa, A.E. Boitano, P.C. Lucas, and V.P. Castle Constitutively active NFkappa B is required for the survival of S-type neuroblastoma J Biol Chem 277 2002 42144 42150
41. W. Wang, H.L. McLeod, and J. Cassidy Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines Int J Cancer 104 2003 504 511
42. 125I]iodo-2′-deoxyuridine in the treatment of colorectal cancer metastatic to the liver J Nucl Med 37 1996 25S 29S
43. 125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts Int J Cancer 110 2004 145 149
44. K.H. Chi, H.E. Wang, Y.S. Wang, S.L. Chou, H.M. Yu, and Y.H. Tseng Antisense thymidylate synthase electrogene transfer to increase uptake of radiolabeled iododeoxyuridine in a murine model J Nucl Med 45 2004 478 484
45. A.F. Collins, H.A. Pearson, P. Giardina, K.T. McDonagh, S.W. Brusilow, and G.J. Dover Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial Blood 85 1995 43 49
46. B.A. Conley, M.J. Egorin, N. Tait, D.M. Rosen, E.A. Sausville, and G. Dover Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors Clin Cancer Res 4 1998 629 634
47. M.A. Carducci, J. Gilbert, M.K. Bowling, D. Noe, M.A. Eisenberger, and V. Sinibaldi A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule Clin Cancer Res 7 2001 3047 3055
48. E. Lemarie, M. Musset, C. Charbonnier, M. Renoux, and G. Renoux Clinical characterization of imuthiol Methods Find Exp Clin Pharmacol 8 1986 51 54
49. E.C. Reisinger, P. Kern, M. Ernst, P. Bock, H.D. Flad, M. Dietrich German DTC Study Group Inhibition of HIV progression by dithiocarb Lancet 335 1990 679 682